An explorative study regarding the effect of l-deprenyl on cognitive and functional recovery in patients after stroke

J Neurol Sci. 2015 Feb 15;349(1-2):117-23. doi: 10.1016/j.jns.2014.12.039. Epub 2015 Jan 3.

Abstract

Introduction: Selegiline (l-deprenyl) is a selective monoamine oxidase type B inhibitor that has been shown to have neurotrophic and anti-apoptotic properties and to protect neurons in different experimental models of cerebral ischaemia. The aim of this explorative study was to investigate whether selegiline could enhance cognitive and functional recovery in stroke survivors.

Methods: This was a randomized controlled study in which patients enrolled within two weeks of stroke underwent a clinical and functional evaluation and a neuropsychological assessment. The patients were given selegiline (10mg/day) or matched placebo once a day for six weeks in addition to standard rehabilitation care.

Results: Of 137 stroke survivors, 47 patients met the inclusion criteria and were randomly assigned to the Study Group (n=23) or the Control Group (n=24). The statistical analysis showed a significant improvement in most neuropsychological tests after two and six weeks in the study group; these improvements were not replicated in the control group. The between-group analysis revealed that the domains of attention and executive functions benefited most from the drug treatment. With regard to functional status, comparison of clinical scores at admission and discharge showed a statistically significant enhancement in both groups without statistically significant differences between the groups.

Conclusions: These preliminary results suggest that selegiline administered in the subacute phase can promote cognitive functioning in stroke patients. Further studies will elucidate whether and how this enhancement can impact on functional recovery in the short and in the long term.

Keywords: Cognitive recovery; Pharmacological agents; Rehabilitation; Selegiline; Stroke; l-Deprenyl.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Attention / drug effects
  • Case-Control Studies
  • Cognition / drug effects*
  • Executive Function / drug effects
  • Female
  • Humans
  • Male
  • Middle Aged
  • Monoamine Oxidase Inhibitors / therapeutic use*
  • Neuropsychological Tests
  • Recovery of Function / drug effects*
  • Selegiline / therapeutic use*
  • Stroke / drug therapy*
  • Stroke / physiopathology

Substances

  • Monoamine Oxidase Inhibitors
  • Selegiline